Drug class profile · refreshed daily from federal data

Opioid Agonist

16 molecules in this class, $1.11B combined CY2024 Part D spend across 23.1M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Opioid Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 16tracked in Part D
CY24 Part D spend: $1.11Bcombined across class
Total Rx claims: 23.1M6.9M unique beneficiaries
Generic mfrs (active): 112across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

01

Oxycodone

Brand: OXAYDO · 14.7M Part D claims (CY24) · 4.7M beneficiaries · First FDA approval: 2000-08-31

18 generic mfrs 254 plans require PA Discontinued

Low NADAC$0.049

→

Avg plan cost$2.84

Part D spend $737.4M 58× spread, current vs floor

Class share

67%

of class CY24 spend

View profile →

02

Fentanyl

Brand: Fentanyl system · 1.2M Part D claims (CY24) · 205K beneficiaries · First FDA approval: 1984-07-11

5 generic mfrs 1102 plans require PA Active FDA shortage

Low NADAC$1.79

→

Avg plan cost$11.32

Part D spend $139.6M 6× spread, current vs floor

Class share

13%

of class CY24 spend

View profile →

03

Morphine

Brand: Duramorph · 3.8M Part D claims (CY24) · 823K beneficiaries · First FDA approval: 1984-09-18

15 generic mfrs 829 plans require PA Active FDA shortage

Low NADAC$0.043

→

Avg plan cost$0.845

Part D spend $108.2M 20× spread, current vs floor

Class share

10%

of class CY24 spend

View profile →

04

Oxymorphone

43K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2010-09-27

7 generic mfrs 0 plans require PA

Low NADAC$1.22

→

Avg plan cost$1.22

Part D spend $29.7M 1× spread, current vs floor

Class share

3%

of class CY24 spend

View profile →

05

Hydromorphone

Brand: Dilaudid · 1.2M Part D claims (CY24) · 345K beneficiaries · First FDA approval: 1972-01-01

8 generic mfrs 164 plans require PA Active FDA shortage

Low NADAC$0.169

→

Avg plan cost$2.34

Part D spend $28.7M 14× spread, current vs floor

Class share

3%

of class CY24 spend

View profile →

06

Loperamide

1.4M Part D claims (CY24) · 709K beneficiaries · First FDA approval: 1991-09-18

8 generic mfrs 0 plans require PA

Low NADAC$0.055

→

Avg plan cost$0.055

Part D spend $24.5M 1× spread, current vs floor

Class share

2%

of class CY24 spend

View profile →

07

Levorphanol

7K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2000-03-31

5 generic mfrs 2 plans require PA

Low NADAC$10.65

→

Avg plan cost$10.65

Part D spend $20.6M 1× spread, current vs floor

Class share

2%

of class CY24 spend

View profile →

08

Methadone

Brand: DISKETS · 830K Part D claims (CY24) · 122K beneficiaries · First FDA approval: 1973-03-14

11 generic mfrs 429 plans require PA

Low NADAC$0.102

→

Avg plan cost$0.213

Part D spend $16.9M 2× spread, current vs floor

Class share

2%

of class CY24 spend

View profile →

09

Meperidine

Brand: DEMEROL · 2K Part D claims (CY24) · 675 beneficiaries · First FDA approval: 1975-01-22

4 generic mfrs 12 plans require PA Active FDA shortage

Low NADAC$0.157

→

Avg plan cost$0.157

Part D spend $1.9M 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

10

Fentanyl Transdermal

— Part D claims (CY24) · First FDA approval: 2020-02-28

Brand-only (no generics)

Low NADAC$6.01

→

Avg plan cost$15.55

Part D spend — 3× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

11

Hydrocodone Bitartrate and Homatropine Methylbromide

Brand: Hycodan · — Part D claims (CY24) · First FDA approval: 2002-09-30

6 generic mfrs Discontinued

Low NADAC$0.103

→

Avg plan cost$0.649

Part D spend — 6× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

12

Hydrocodone and Apap

Brand: Norco · — Part D claims (CY24) · First FDA approval: 2022-11-23

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

13

Morphine Tincture

Brand: Opium Tincture Deodorized · — Part D claims (CY24) · First FDA approval: 2011-02-25

Brand-only (no generics)

Low NADAC$2.86

→

Avg plan cost$2.86

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

14

Oxycodone and Acetaminophen

Brand: ENDOCET · — Part D claims (CY24) · First FDA approval: 1983-12-07

17 generic mfrs 12 plans require PA Discontinued

Low NADAC$0.117

→

Avg plan cost$1.42

Part D spend — 12× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

15

Sufentanil

Brand: Dsuvia · — Part D claims (CY24) · First FDA approval: 2005-07-26

2 generic mfrs Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

16

Tramadol and Acetaminophen

— Part D claims (CY24) · First FDA approval: 2009-12-17

6 generic mfrs 3 plans require PA

Low NADAC$0.116

→

Avg plan cost$0.116

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

Related questions.

Q&A librarySourced · reviewed quarterly

pricingWhat is NADAC?pricingIs NADAC the same as my PBM cost?pricingWhat is spread pricing?pricingWhat is a NADAC pass-through PBM contract?pricingWhat's the difference between AWP, MAC, and NADAC?pricingWhat is a dispensing fee in a PBM contract?

Browse all canonical questions →